FDA Evaluates Potential Regulatory Pathway for Testosterone Therapy in Menopausal Women

On September 17, 2026, the U.S. Food and Drug Administration convened a hybrid public workshop at its White Oak Campus at 10903 New Hampshire Avenue in Maryland to formally evaluate the use of testosterone therapy in menopausal women. The meeting, hosted jointly by the FDA's Office of Women's Health and the Center for Drug Evaluation and Research, brought together federal regulators, clinical researchers, and patient advocates to assess the current scientific evidence. The agency opened a 60-day public comment period under docket FDA-2026-N-5479 to collect broad commentary on the hormone's risks and benefits, accepting submissions through October 19, 2026.[1][2]

The regulatory review addresses a growing disconnect between clinical practice and approved treatments. Currently, there is no FDA-approved testosterone product specifically indicated for women in the United States. Despite this regulatory absence, off-label prescribing has risen sharply over the past 10 years as women seek relief from menopause symptoms, particularly hypoactive sexual desire disorder (HSDD). To meet patient demand, clinicians frequently prescribe lower doses of testosterone formulations approved for men, such as 1% gels, or rely on custom-compounded products from specialized pharmacies.[1][3]

During the livestreamed event, which ran from 9:00 a.m. to 4:30 p.m. Eastern Time, experts highlighted the practical challenges this off-label reliance creates for both patients and healthcare providers. Using male formulations requires careful dose division, which increases the margin for error. Furthermore, these products often contain absorption enhancers designed specifically for male physiology, complicating accurate dosing and pharmacokinetics for women.[2][3]

An approved female-specific drug could resolve many of these logistical hurdles. Medical experts at the workshop noted that a dedicated product would offer standardized labeling and clear safety-monitoring guidance. It could also potentially improve insurance coverage for patients who currently pay out of pocket for compounded creams or off-label prescriptions, democratizing access to the therapy.[3]

However, the FDA identified several areas where clinical data remains insufficient to support immediate approval. While short-term safety data for physiologic female doses is generally reassuring, the agency noted an absence of comprehensive long-term studies. Regulators expressed specific concern regarding the lack of decades-long safety data tracking cardiovascular outcomes and breast cancer risks in women using systemic testosterone.[1][2]

"The purpose of the workshop is to examine the current scientific evidence and critical knowledge gaps related to testosterone use in menopausal women to help inform future research and potential drug development in this area," the FDA stated in its meeting announcement. Beyond sexual function, the workshop also examined testosterone's potential role in cognition, mood, and musculoskeletal health—areas where clinical evidence has not yet established effectiveness despite widespread social media claims promoting the hormone as a universal menopause cure.[1][2]

International regulatory bodies have already taken action on this front, creating a sharp contrast with U.S. policy. Health authorities in 4 nations—Australia, New Zealand, the United Kingdom, and South Africa—have approved or licensed testosterone products specifically for female patients to treat HSDD. During the FDA meeting, speakers pointed to these international precedents, noting the unmet needs of American women who lack access to similar standardized, regulated therapies.[3]

The FDA's request for public input ahead of the hearing drew hundreds of submissions, with many women describing enhanced libido, energy levels, and overall quality of life while using the hormone. The agency stated that the information gathered from the workshop and the public comment period will help inform future research requirements and potential drug development pathways. While the September 17 meeting did not result in an immediate approval decision, it establishes the foundational regulatory framework required to bring a female-specific testosterone treatment to the U.S. market.[1][2][3]